Open Scanner

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Atea Pharmaceuticals Inc

AVIR
Current price
3 USD +0.01 USD (+0.33%)
Last closed 3.01 USD
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 260 736 512 USD
Yield for 12 month -35.62 %
Week
Month
Year
AVIR
21.11.2021 - 28.11.2021

Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. Its lead product candidate is AT-527, an oral antiviral candidate that is in Phase III SUNRISE-3 clinical trial for the treatment of patients with COVID-19. The company also develops AT-752, a drug that is in Phase II clinical trial for the treatment and prophylaxis of dengue; and AT-281, a pharmaceutically acceptable salt for the treatment or prevention of an RNA viral infection, including dengue fever, yellow fever, and Zika virus, as well as Ruzasvir, an investigational NS5A inhibitor for the treatment of chronic HCV infection. It also develops a co-formulated, oral, pan-genotypic fixed dose combination of bemnifosbuvir and ruzasvir for the treatment of hepatitis C virous (HCV); It has a license agreement with Merck & Co, Inc. development, manufacture, and commercialization of ruzasvir for the treatment of HCV. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts. Address: 125 Summer Street, Boston, MA, United States, 02110

Analytics

WallStreet Target Price

4 USD

P/E ratio

Dividend Yield

Current Year

Last Year

+351 367 000 USD

Current Quarter

Last Quarter

Current Year

Last Year

+351 367 000 USD

Current Quarter

Last Quarter

Key Figures AVIR

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -137 866 000 USD
Operating Margin TTM
PE Ratio
Return On Assets TTM -13.35 %
PEG Ratio
Return On Equity TTM -21.08 %
Wall Street Target Price 4 USD
Revenue TTM 192 180 000 USD
Book Value 6.97 USD
Revenue Per Share TTM 2.31 USD
Dividend Share
Quarterly Revenue Growth YOY 295.2 %
Dividend Yield
Gross Profit TTM -81 936 000 USD
Earnings Share -1.57 USD
Diluted Eps TTM -1.57 USD
Most Recent Quarter III 2023
Quarterly Earnings Growth YOY 264.1 %
Profit Margin

Dividend Analytics AVIR

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History AVIR

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield
Last Split Factor
Payout Ratio
Last Split Date
Dividend Date

Stock Valuation AVIR

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue 58.974
Price Sales TTM 1.9026
Enterprise Value EBITDA 2.1178
Price Book MRQ 0.4468

Financials AVIR

1 year
3 years
5 years
10 years
Results 2019 Dynamics

Technical indicators AVIR

For 52 weeks

2.77 USD 5.19 USD
50 Day MA 3.03 USD
Shares Short Prior Month 2 758 143
200 Day MA 3.44 USD
Short Ratio 8.15
Shares Short 3 617 614
Short Percent 5.64 %